[Announcement of New Base Establishment] Opening of a new GMP manufacturing facility for oligonucleotides.
Ajinomoto Bio-Pharma Services and Gene Design will strengthen its contract development and production system from the early stages of development to late stages and market launch by introducing large-scale production facilities. With the establishment of the new site, the production volume per lot will expand to the kilogram level. By combining our production capacity with the mass production technology of the Ajinomoto Group, a flexible and seamless supply system will be established, transitioning from conventional μg manufacturing to over 100 kg. [Overview] - Newly established within the research facility in Ibaraki City, Osaka Prefecture - Combined with the mass production technology of the Ajinomoto Group (AJIPHASE technology) - Establishing a supply system from conventional μg to over 100 kg *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
For more details, please refer to the PDF document or feel free to contact us.
Price information
Please contact us.
Delivery Time
Applications/Examples of results
For more details, please refer to the PDF document or feel free to contact us.
catalog（1）
Download All Catalogs
Company information
Ajinomoto Bio-Pharma Services and GeneDesign, Inc. are engaged in the production of oligonucleotides, incorporating the latest technologies and patent licenses from various research institutions. We supply distinctive nucleic acid materials, including the introduction of artificially modified nucleic acids and the addition of functional molecules, contributing to the development of new technologies in the gene-related fields (such as drug development, diagnostic technology development, and bio-research technology development). Currently, the demand for various synthetic nucleic acids is expanding from cell culture levels to animal testing and further to clinical trials. Our company has established a system capable of supplying everything from research reagents to investigational drugs at all scales, and we are advancing research and development daily as a company that can significantly contribute to the creation of nucleic acid pharmaceuticals and the practical application of diagnostic systems. For the future of medicine, we aim to be a company that contributes to the welfare and health of people through the development of nucleic acid manufacturing technologies, actively working on the development of next-generation nucleic acid drugs and diagnostic materials.
![[Technology and Achievements] Drug Discovery Support](https://image.mono.ipros.com/public/product/image/c98/2000706985/IPROS26837429273121686597.png?w=280&h=280)
